Mergers & Acquisitions - Merck Serono

Filter

Current filters:

Merck Serono

Popular Filters

82 to 106 of 904 results

Alvogen takes 67% stake in Lotus Pharma

17-01-2014

Privately-owned US generics firm Alvogen revealed that, last month, it agreed to become the majority…

AlvogenAsia-PacificGenericsLotus PharmaceuticalsMergers & Acquisitions

Johnson & Johnson offered $4.15 billion for its diagnostics unit

Johnson & Johnson offered $4.15 billion for its diagnostics unit

17-01-2014

After days of speculation about divestitures by US health care major Johnson & Johnson, the company last…

Johnson & JohnsonMergers & AcquisitionsPharmaceutical

Biotoscana to buy United Medical to create regional specialty pharma group in South America

14-01-2014

Colombia-based Grupo Biotoscana has signed an agreement to acquire Brazilian drugmaker United Medical…

Grupo BiotoscanaMergers & AcquisitionsPharmaceuticalSouth AmericaUnited Medical

Agenus to acquire Switzerland’s 4-Antibody AG

14-01-2014

US biotech firm Agenus has entered into a definitive agreement to acquire 4-Antibody AG, a private Switzerland-headquartered…

4-Antibody AGAgenusBiotechnologyGITRMergers & AcquisitionsOncologyOX40

McKesson acquisition of German rival Celesio fails

14-01-2014

USA-based health care service and information technology giant McKesson Corp revealed yesterday that…

CelesioMcKessonMergers & AcquisitionsPharmaceutical

Galena Biopharma acquires Mills Pharmaceuticals

14-01-2014

US drugmaker Galena Biopharma revealed that it has acquired Mills Pharmaceuticals, which has the worldwide…

AnagrelideGalena BioPharmaHematologyMergers & AcquisitionsMills PharmaceuticalsPharmaceutical

Big pharma's need to tap M&A for growth will persist in 2014, while dealmaking landscape becomes more competitive, says EY

13-01-2014

Big pharma stayed on the sidelines in the 2013 mergers and acquisitions market despite a continuing need…

GlobalMergers & AcquisitionsPharmaceutical

Regeneron amends investor agreement with Sanofi

Regeneron amends investor agreement with Sanofi

13-01-2014

US biotech firm Regeneron Pharmaceuticals says it has amended and restated its investor agreement with…

BiotechnologyMergers & AcquisitionsRegeneronSanofi

Pharma M&A deals in 2013 down, but values marginally higher

Pharma M&A deals in 2013 down, but values marginally higher

13-01-2014

Merger and acquisition activity in the pharmaceutical, biotechnology and generic drugs sectors continued…

BiotechnologyGlobalMergers & AcquisitionsPharmaceutical

Alnylam to acquire Merck’s Sirna Therapeutics

Alnylam to acquire Merck’s Sirna Therapeutics

13-01-2014

US RNAi therapeutics specialist Alnylam Pharmaceuticals says it has reached agreement to acquire US pharma…

Alnylam PharmaceuticalsBiotechnologyMerck & CoMergers & AcquisitionsSirna Therapeutics

Akorn gains rights to Betimol from Santen

10-01-2014

US niche generic firm Akorn has acquired the New Drug Application and all rights to Betimol (timolol…

AkornBetimolMergers & AcquisitionsOphthalmicsPharmaceuticalSanten Pharmaceuticals

Endo divests remainder of HealthTronics for up to $130 million

09-01-2014

Endo Health Solutions says it has entered into a definitive agreement to sell its HealthTronics business…

Endo Health SolutionshealthTronicsMergers & AcquisitionsPharmaceutical

NuPathe receives counter offer from Teva topping Endo bid

09-01-2014

US drugmaker NuPathe – currently the subject of a takeover bid from USA-based Endo Health Solutions…

Endo Health SolutionsMergers & AcquisitionsNuPathePharmaceuticalTeva Pharmaceutical Industries

Merck Serono appoints Steven Hildemann as global chief medical officer

Merck Serono appoints Steven Hildemann as global chief medical officer

09-01-2014

Merck Serono, the biotech unit of Germany’s Merck KGaA (MRK: DE), has named Steven Hildemann as global…

BiotechnologyBoardroomGermanyMerck Serono

Forest Labs to spend $2.9 billion on acquiring Aptalis

Forest Labs to spend $2.9 billion on acquiring Aptalis

09-01-2014

Confirming recent speculative reports, US drugmaker Forest Laboratories says it has entered into a definitive…

AptalisForest LaboratoriesGastro-intestinalsMergers & AcquisitionsPharmaceuticalRare diseases

Eddingpharm acquires global rights to oncology assets, including telatinib, from ACT Biotech

08-01-2014

Chinese drug firm Eddingpharm has entered into an asset purchase agreement (APA) with a private, venture…

ACT BiotechEddingpharmMergers & AcquisitionsOncologyPharmaceuticaltelatinib

moksha8 files Viibryd and Colobreathe in Brazil; amends Forest alliance

06-01-2014

Brazil-based pharma firm moksha8 has filed applications with the Brazilian regulatory authority, ANVISA,…

BrazilColoBreatheForest LaboratoriesLicensingMerck SeronoMoksha8NeurologicalPharmaceuticalRare diseasesRegulationSouth AmericaViibryd

Probiodrug sells its CDK9 inhibitor program to AstraZeneca

Probiodrug sells its CDK9 inhibitor program to AstraZeneca

06-01-2014

Privately-held German company Probiodrug says it has transferred its experimental cyclin-dependent kinase…

AstraZenecaInflammatory diseasesMergers & AcquisitionsOncologyPharmaceuticalProbiodrug

Ikaria sells commercial business to Madison Dearborn for $1.6 billion

03-01-2014

US critical care company Ikaria says that its investor group and employee shareholders have reached a…

IkariaInomaxMergers & AcquisitionsPharmaceuticalRespiratory and Pulmonary

Walvax Biotech to take 64% stake in Genor BioPharma for around $49 million

Walvax Biotech to take 64% stake in Genor BioPharma for around $49 million

31-12-2013

China’s Walvax Biotech has revealed it plans to acquire a controlling 64% equity stake in Shanghai’s…

Asia-PacificBiosimilarsBiotechnologyChinaMergers & AcquisitionsOncology

82 to 106 of 904 results

Back to top